Moving to anti-PD-L1 agents, atezolizumab monotherapy showed inconsistent results in phase 1a and phase 2 trials [22,24], while durvalumab demonstrated durable clinical activity in certain patients with pretreated ES-SCLC in a phase 1/2 trial [25]. Here, CD274 is linked to small cell lung carcinoma.